HIGHLIGHTS
- who: Liang Shi from the Department of General Surgery, Nanjing First, Nanjing Medical University, Nanjing, China have published the article: Antitumour effects of apatinib in progressive, metastatic differentiated thyroid cancer (DTC), in the Journal: (JOURNAL) of November/26,/2019
- what: The aim of this study was to evaluate the antitumour effect of and the combination therapy with (RAI) in patients with progressive DTC. The study showed that apatinib, a small-molecule tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor 2 (VEGFR2) and platelet-derived growth factor receptor (PDGFR) u03b2 , demonstrates significant clinical benefits . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.